Project description
An enlightened monitoring system reduces risks associated with localised radiotherapy
The ability to deliver medicine exactly where it is needed typically results in more effective treatment at lower doses with fewer side-effects than treatments with lower spatial or temporal resolution. Just as a nasal inhaler works on this principle, radiation to treat cancer has benefited from increasingly localised administration through brachytherapy (placing encapsulated radioactive material inside the body in the area of cancerous tissue). Given that radiation can have much more serious side-effects on healthy cells than a nasal inhalant, clinicians monitor its administration in real-time. The EU-funded ORIGIN project is developing a vastly improved methodology, a photonics-based optical dose imaging and localisation system whose resolution will significantly reduce the overall risk of treatment error.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
- Limerick
Ireland
See on map
Participants (10)
1050 Brussel
See on map
Participation ended
3590 Diepenbeek
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
BT7 1NN Belfast
See on map
Participation ended
06054 Nice Cedex
H91 HHTO Galway
See on map
Participation ended
13125 Berlin
21100 Varese
See on map
33011 Oviedo
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
33001 Oviedo
See on map
13125 Berlin
See on map